---
title: "References"
description: "Complete numbered reference list for the psoriasis book, including primary research articles, reviews, guidelines, and registry data."
sidebar:
  order: 26
---

1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. *JAMA*. 2020;323(19):1945-1960. doi:10.1001/jama.2020.4006. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32427307/)

2. Sieminska I, Pieniawska M, Grzywa TM. The immunology of psoriasis — current concepts in pathogenesis. *Clin Rev Allergy Immunol*. 2024;66(2):164-191. doi:10.1007/s12016-024-08991-7. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11193704/)

3. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. *Lancet*. 2021;397(10281):1301-1315. doi:10.1016/S0140-6736(20)32549-6. [Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32549-6/abstract)

4. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. *J Allergy Clin Immunol*. 2017;140(3):645-653. doi:10.1016/j.jaci.2017.07.004. [Full text](https://www.jacionline.org/article/S0091-6749(17)31197-1/fulltext)

5. Dand N, Mahil SK, Capon F, et al. GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. *Nat Commun*. 2025;16:2014. doi:10.1038/s41467-025-56719-8. [Nature](https://www.nature.com/articles/s41467-025-56719-8)

6. Capon F. Psoriasis and genetics. *Acta Derm Venereol*. 2020;100(3):adv00030. [Full text](https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3384)

7. Gelfand JM et al. A partitioned 88-loci psoriasis genetic risk score reveals HLA and non-HLA contributions to clinical phenotypes in a Newfoundland psoriasis cohort. *Front Genet*. 2023;14:1141010. [Frontiers](https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2023.1141010/full)

8. Strange A, Capon F, Spencer CCA, et al. Genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. *Nat Genet*. 2010;42(11):985-990. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3749730/)

9. El-Boghdady NA et al. The genetic susceptibility to psoriasis and the relationship of linked genes to our treatment options. *Cureus*. 2023;15(7):e42415. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10418823/)

10. Li M, et al. Genetics of psoriasis: a basis for precision medicine. *Precis Clin Med*. 2019;2(2):120-130. doi:10.1093/pcmedi/pbz010. [Oxford Academic](https://academic.oup.com/pcm/article/2/2/120/5522496)

11. Xiong Y, Xue J, Tong M, Xu T, Bai X. Dynamic trend analysis of global psoriasis burden from 1990 to 2021. *Front Public Health*. 2025;13:1518681. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12283580/)

12. Dimmock PW, Aalemi AK, Parisi R, et al. Global epidemiology of psoriasis: Global Psoriasis Atlas 2024 update. *Br J Dermatol*. 2024;191(Suppl_3):ljae360.061. [Oxford Academic](https://academic.oup.com/bjd/article/191/Supplement_3/ljae360.061/7916197)

13. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. *J Eur Acad Dermatol Venereol*. 2017;31(2):205-212. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27573025/)

14. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. *J Invest Dermatol*. 2013;133(2):377-385. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23014338/)

15. Dairov A, Issabekova A, Sekenova A, et al. Prevalence, incidence, gender and age distribution, and economic burden of psoriasis worldwide and in Kazakhstan. *J Clin Med Kazakhstan*. 2024;21(2):18-30. [Full text (PDF)](https://www.clinmedkaz.org/download/prevalence-incidence-gender-and-age-distribution-and-economic-burden-of-psoriasis-worldwide-and-in-14497.pdf)

16. Zhu X, Zheng A, et al. Triggers for the onset and recurrence of psoriasis: a review and update. *Cell Commun Signal*. 2024;22:108. doi:10.1186/s12964-023-01381-0. [Springer](https://link.springer.com/article/10.1186/s12964-023-01381-0)

17. Ko SH, et al. Lifestyle changes for treating psoriasis. *Cochrane Database Syst Rev*. 2019;7:CD011972. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6629583/)

18. Naldi L. Psoriasis and smoking: links and risks. *Psoriasis (Auckl)*. 2016;6:65-71. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC5683129/)

19. Luca M, et al. The role of smoking in psoriasis. *Medicina (Kaunas)*. 2024;60(5):856. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11110215/)

20. Zhou W, et al. Tobacco smoking negatively influences the achievement of greater than three-quarters reduction in PASI after eight weeks of treatment. *Tob Induc Dis*. 2024;22:60. [Full text](https://www.tobaccoinduceddiseases.org/Tobacco-smoking-negatively-influences-the-achievement-of-greater-than-three-quarters,184143,0,2.html)

21. Caso F, et al. The role of lifestyle and nutrition in psoriasis: current status of knowledge and interventions. *Dermatol Ther*. 2022;35(11):e15811. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC9541512/)

22. Takahashi H, Iizuka H. Cardiovascular and metabolic diseases comorbid with psoriasis: beyond the skin. *Intern Med*. 2012;51(18):2471-2477. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC5519460/)

23. Hu SC, Lan CE. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. *Int J Mol Sci*. 2017;18(10):2211. [MDPI](https://www.mdpi.com/1422-0067/18/10/2211)

24. Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. *Clin Cosmet Investig Dermatol*. 2014;7:119-132. [Dove Press](https://www.dovepress.com/psoriasis-and-comorbidities-links-and-risks-peer-reviewed-fulltext-article-CCID)

25. Mehta NN, et al. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. *J Am Coll Cardiol*. 2021;77(13):1670-1680. [JACC](https://www.jacc.org/doi/10.1016/j.jacc.2021.02.009)

26. National Psoriasis Foundation. What are the related medical conditions of psoriasis? Updated 2024. [Website](https://www.psoriasis.org/related-conditions/)

27. ten Bergen LL, et al. The TNF/IL-23/IL-17 axis — head-to-head trials comparing different biologics in psoriasis treatment. *Scand J Immunol*. 2020;92(4):e12946. [Wiley](https://onlinelibrary.wiley.com/doi/10.1111/sji.12946)

28. Fatani M, et al. Review on recommendations on the use of biologic treatments for psoriasis. *Expert Opin Biol Ther*. 2025. [Taylor & Francis (PDF)](https://www.tandfonline.com/doi/pdf/10.1080/14712598.2025.2495986)

29. Comparative efficacy of TNF-alpha inhibitors, IL-17 and IL-23 inhibitors. *IJFMR*. 2024;6(6):29806. [Full text (PDF)](https://www.ijfmr.com/papers/2024/6/29806.pdf)

30. Balogh EA, et al. From the Masterclasses in Dermatology 2024: Updates in psoriasis treatments. *Dermatol Ther (Heidelb)*. 2025;15:539-554. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11896623/)

31. Dey AK, et al. Emerging oral therapies for the treatment of psoriasis: a review of pipeline agents. *Pharmaceuticals (Basel)*. 2024;17(1):137. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10819460/)

32. Gopika M, et al. Advances in psoriasis research: from pathogenesis to therapeutics. *Life Sci*. 2024;355:122935. [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S0024320524005812)

33. Al-Kufi SNH, et al. Advancements in understanding and treating psoriasis: a comprehensive review. *PeerJ*. 2025;13:e19354. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12047224/)

34. Tsankov NK, et al. Advances in understanding the immunological pathways in psoriasis. *Int J Mol Sci*. 2019;20(3):739. [MDPI](https://www.mdpi.com/1422-0067/20/3/739)

35. Armstrong AW, et al. Psoriasis. *Nat Rev Dis Primers*. 2025;11:46. [Nature](https://www.nature.com/articles/s41572-025-00630-5)

36. Wang X, et al. Global burden of psoriasis from 1990 to 2021 and potential factors: a systematic analysis. *J Invest Dermatol*. 2025 (in press). [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S0022202X25024157)

37. Li X, et al. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. *Int Immunopharmacol*. 2019;62:46-58. [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S1567576918302716)

38. Fotiadou C, et al. New therapies in the biological treatment of psoriasis: a review. *Biologics*. 2025;5(2):19. [MDPI](https://www.mdpi.com/2313-5786/5/2/19)

39. Liu J, et al. Critical role of environmental factors in the pathogenesis of psoriasis. *J Dermatol*. 2017;44(8):863-872. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28349593/)

40. Xie X, et al. Biologics for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. *Dermatol Ther (Heidelb)*. 2025;15:1497-1527. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12126413/)

41. Chen H, et al. Systemic psoriasis: from molecular mechanisms to global management strategies. *Clin Rev Allergy Immunol*. 2025. doi:10.1007/s12016-025-09089-4. [Springer](https://link.springer.com/article/10.1007/s12016-025-09089-4)

42. Johnson M. What we know about psoriasis comorbidities and their management. *Dermatology Education Foundation*. 2024. [Website](https://dermnppa.org/what-we-know-about-psoriasis-comorbidities-and-their-management/)

43. Li T, et al. A practical guide to biologic treatments for psoriasis in Asia. *Asian Pac J Allergy Immunol*. 2025 (online). [Full text (PDF)](https://apjai-journal.org/wp-content/uploads/2025/10/7_AP-240425-2072.pdf)

44. Cheng Y, et al. GWAS and comprehensive analysis of psoriasis in the Taiwanese population. *Mol Med Rep*. 2024;30(1):104. [Spandidos](https://www.spandidos-publications.com/10.3892/mmr.2024.13239)

45. Egilman AC, Kesselheim AS, Avorn J, Raymakers AJN, Rome BN. Use of efficiency frontiers to align prices and clinical benefits of biologic therapies for plaque psoriasis. *JAMA Dermatol*. 2024;160(4):409-416. doi:10.1001/jamadermatol.2023.6236. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10882509/)

46. Rome BN, Han J, Mooney H, Kesselheim AS. Use and cost of first-line biologic medications to treat plaque psoriasis in the US. *JAMA Dermatol*. 2025;161(6):622-628. doi:10.1001/jamadermatol.2025.0669. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40238112/)

47. National Psoriasis Foundation. Biosimilars for psoriasis and psoriatic arthritis. Updated March 24, 2025. [Website](https://www.psoriasis.org/biosimilars/)

48. National Psoriasis Foundation. Current biologics on the market for psoriatic disease. [Website](https://www.psoriasis.org/current-biologics-on-the-market/)

49. Segal. Specialty dermatological drug cost trends Q3 2025. [Website](https://www.segalco.com/consulting-insights/q3-2025-trends-focus-specialty-dermatological-drugs)

50. Dermatology Advisor. Biosimilars for psoriasis treatment. November 5, 2025. [Website](https://www.dermatologyadvisor.com/features/biosimilars-for-psoriasis/)

51. Lewitt G, et al. Psoriasis therapies in 2024 and beyond. *Dermatology Times*. 2024. [Website](https://www.dermatologytimes.com/view/psoriasis-therapies-in-2024-and-beyond)

52. Brajac I, Gruber F. History of Psoriasis. In: O'Daly J, editor. *Psoriasis — A Systemic Disease*. Rijeka: IntechOpen; 2012. p. 57-68. doi:10.5772/27640. [IntechOpen](https://doi.org/10.5772/27640)

53. Holubar K. Psoriasis and parapsoriasis: since 200 and 100 years, respectively. *J Eur Acad Dermatol Venereol*. 2003;17(2):126-127. doi:10.1046/j.1468-3083.2003.00622.x. [JEADV](https://doi.org/10.1046/j.1468-3083.2003.00622.x)

54. Willan R. *On Cutaneous Diseases*. Vol. 1. London: J. Johnson; 1808. [Internet Archive](https://archive.org/details/2577014R.nlm.nih.gov)

55. Auspitz H. Ueber das Verhaltniss der Oberhaut zur Papillarschicht. *Archiv fur Dermatologie und Syphilis*. 1870;2:24-58. doi:10.1007/BF01822714. [Springer](https://doi.org/10.1007/BF01822714)

56. Ingram JT. The approach to psoriasis. *Br Med J*. 1953;2(4836):591-594. doi:10.1136/bmj.2.4836.591. [BMJ](https://doi.org/10.1136/bmj.2.4836.591)

57. Dennis M, Bhutani T, Koo J, Liao W. The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis. *J Dermatolog Treat*. 2013;24(4):319-327. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3735239/)

58. Edmundson WF, Guy WB. Treatment of psoriasis with folic acid antagonists. *AMA Arch Derm*. 1958;78:200-203. [PubMed](https://pubmed.ncbi.nlm.nih.gov/13571257/)

59. Mueller W, Herrmann B. Cyclosporin A for psoriasis. *N Engl J Med*. 1979;301:555. [PubMed](https://pubmed.ncbi.nlm.nih.gov/460325/)

60. Eedy DJ, Burrows D, Bridges JM, Jones FG. Clearance of severe psoriasis after allogenic bone marrow transplantation. *BMJ*. 1990;300(6729):908. doi:10.1136/bmj.300.6729.908. [BMJ](https://doi.org/10.1136/bmj.300.6729.908)

61. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. *Arch Dermatol*. 2010;146(8):891-895. doi:10.1001/archdermatol.2010.186. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20713823/)

62. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. *J Invest Dermatol*. 2015;135(4):984-991. doi:10.1038/jid.2014.530. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25521458/)

63. Williams K, Lada G, Reynolds NJ, et al. Risk of suicide and suicidality in patients with moderate to severe psoriasis: results from BADBIR. *Clin Exp Dermatol*. 2025;50(4):804-811. doi:10.1093/ced/llae449. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39425683/)

64. Griffiths CEM, Fava M, Miller AH, et al. Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis. *Psychother Psychosom*. 2017;86(5):260-267. doi:10.1159/000479163. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28903122/)

65. Abboud E, Chrayteh D, Boussetta N, et al. Skin hepcidin initiates psoriasiform skin inflammation via Fe-driven hyperproliferation and neutrophil recruitment. *Nat Commun*. 2024;15(1):6718. doi:10.1038/s41467-024-50993-8. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11306357/)

66. Olafsson S, Rodriguez E, Lawson ARJ, et al. Effects of psoriasis and psoralen exposure on the somatic mutation landscape of the skin. *Nat Genet*. 2023;55(11):1892-1900. doi:10.1038/s41588-023-01545-1. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37884686/)

67. Bissonnette R, Soung J, Hebert AA, et al. Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents. *N Engl J Med*. 2025;393(18):1784-1795. doi:10.1056/NEJMoa2504187. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41191940/)

68. Tehlirian C, et al. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial. *JAMA Dermatol*. 2024. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39167366/)

69. Nielsen ML, Thein D, Rasmussen MK, et al. Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: A nationwide cohort study. *J Am Acad Dermatol*. 2023;88(6):1378-1381. doi:10.1016/j.jaad.2023.01.029. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36739903/)

70. Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal effect on psoriasis in pregnancy and post partum. *Arch Dermatol*. 2005;141(5):601-606. doi:10.1001/archderm.141.5.601. [PubMed](https://pubmed.ncbi.nlm.nih.gov/15793512/)

71. Mariette X, Forger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. *Ann Rheum Dis*. 2018;77(2):228-233. doi:10.1136/annrheumdis-2017-212196. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29030361/)

72. Jeong YD, Jo H, Cho H, et al. Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes: Findings from WHO Pharmacovigilance Study. *Int Arch Allergy Immunol*. 2025;186(6):579-593. doi:10.1159/000542217. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39626647/)
